Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Company Overview - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity, pathogen-specific bacteriophage therapeutics aimed at treating antibiotic-resistant and difficult-to-treat bacterial infections [3] - The company utilizes proprietary bacteriophage-based technology and is advancing a broad pipeline of natural and synthetic phage candidates targeting pathogens such as Pseudomonas aeruginosa and Staphylococcus aureus [3] Upcoming Events - The CEO of Armata, Dr. Deborah Birx, will participate in a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference in New York from September 8-10, 2025 [1] - Armata's presentation is scheduled for September 10, from 1:30-2:00 PM ET [2]